Leading International Fungal Infection (LIFE) has been supported by the 20 year old UK charity the Fungal Infection Trust. LIFE is dedicated to improving health in those with fungal disease (infection and allergy) through education. The overall goal is to greatly improve fungal infection outcomes in patients through healthcare professional awareness, diagnostic acumen, improved diagnosis and selection of the appropriate antifungal therapies, worldwide.
LIFE is led by Professor David Denning.
David Denning is an internationally recognised clinician with expertise in fungal diseases. He manages the UK’s National Aspergillosis Centre in Manchester, the world’s only such centre. David Denning has published more than 500 papers, books and book chapters and lectures worldwide. His writings have been cited over 60,000 times and he has successfully lead many major international collaborative science, diagnostic and treatment projects and clinical guidelines, with subsequent publication in Nature, the New England Journal of Medicine and the Lancet. He is the Founder of two University spinout biotechnology companies – F2G Ltd (antifungal drug discovery and development) and Myconostica Ltd (molecular diagnostic tests for fungi).
David is Chairman of the Editorial Board of The Aspergillus Website (1998-) accessed by >100,000 computers per month and the educational LIFE website. He has chaired the Scientific Committees of several international fungal infection meetings and co-chairs the alternate year Advances Against Aspergillosis meetings, attracting ~400 delegates from >120 countries.
Dr Denning and family hold Founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company. He acts or has recently acted as a consultant to Scynexis, Pulmatrix, Zambon, iCo Therapeutics, Roivant, Biosergen and Fujifilm. In the last 3 years, he has been paid for talks on behalf of Dynamiker, Hikma, Gilead, Merck, Mylan and Pfizer. He is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group and the British Society for Medical Mycology Standards of Care committee.
David is Chief Executive of GAFFI, with responsibility for all functions and advocacy outside of Kenya. He is part time.
Beth Bradshaw, Editor in Chief and lead writer.
Beth joined the team in 2017 as a Medical Writer & Web Manager. As well as LIFE Worldwide, she has worked on the Aspergillus & Aspergillosis website and the NAC Patients website. She previously worked as the Publications Manager for the West Midlands Regional Genetics Laboratory and an Associate Medical Writer with Ashfield Healthcare Communications. Before that she completed her PhD in molecular microbiology (antibiotic discovery and Streptomyces chromatin-like proteins) at the John Innes Centre (UEA) and a postdoc in yeast synthetic biology at TU Delft (Netherlands).
- David Perlin
- Thomas Harrison
- Malcolm Richardson
- Juan Luis Rodríguez Tudela
- Arunaloke Chakrabarti
- Arnaldo Lopes Colombo
- Tania Sorrell
A new version of the LIFE Worldwide is currently under construction and will go live in summer 2019. Visit http://fungaleducation.org/ to track our progress!